SC

Sophrosyne Capital Portfolio holdings

AUM $11.5M Turnover 56.25%
1-Year Est. Return 17.82%
This Fund
S&P 500
This Quarter Est. Return
+0.69%
1 Year Est. Return
+17.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$98.2M
AUM Growth
-$16M
Cap. Flow
-$12.8M
Cap. Flow %
-13.02%
Top 10 Hldgs %
57.17%
Holding
92
New
14
Increased
16
Reduced
24
Closed
27
Avg Time Held
0.5 years
Top 10 Avg Time Held
0.6 years
Top 20 Avg Time Held
0.5 years

Top Buys

Rank Stock Value
1
DRRX icon
DURECT Corp
DRRX
+$1.78M
2
BKNG icon
Booking.com
BKNG
+$1.68M
3
RTK
Rentech, Inc.
RTK
+$1.66M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$1.33M
5
CDZI icon
Cadiz
CDZI
+$1.16M

Top Sells

Rank Stock Value
1
SYT
Syngenta Ag
SYT
+$6.05M
2
LSAK icon
Lesaka Technologies
LSAK
+$3.8M
3
TLPH icon
Talphera
TLPH
+$2.99M
4
CUTR icon
Cutera, Inc.
CUTR
+$1.56M
5
DRTX
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
+$1.42M

Sector Composition

Rank Sector Weight
1 Healthcare 44.84%
2 Technology 18.47%
3 Financials 8.1%
4 Communication Services 7.26%
5 Materials 6.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BEAT icon
1
DELISTED
BioTelemetry, Inc.
BEAT
$8.29M 8.44%
1,155,974
+57,800
+5% +$460K
2013 Q2
4 quarters
MSTR icon
2
Strategy Inc
MSTR
$60.7B
$7.17M 7.3%
510,000
-56,630
-10% -$723K
2013 Q2
4 quarters
BFYT
3
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
$6.88M 7.01%
558,870
+109,025
+24% +$1.12M
2014 Q1
1 quarter
ZLTQ
4
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$6.51M 6.63%
428,704
+40,700
+10% +$696K
2013 Q2
4 quarters
FLNA icon
5
Filana Therapeutics
FLNA
$34.8M
$5.47M 5.57%
135,909
+1,664
+1% +$61.6K
2013 Q3
3 quarters
ARCT icon
6
Arcturus Therapeutics
ARCT
$323M
$5.25M 5.35%
43,368
+4,331
+11% +$523K
2013 Q3
3 quarters
BDSI
7
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$4.77M 4.86%
395,276
-122,386
-24% -$1.16M
2013 Q2
4 quarters
MEET
8
DELISTED
The Meet Group, Inc. Common Stock
MEET
$4.52M 4.61%
1,662,827
-267,308
-14% -$666K
2013 Q2
4 quarters
PCYO icon
9
Pure Cycle
PCYO
$270M
$4.37M 4.45%
646,000
+30,000
+5% +$171K
2013 Q2
4 quarters
CSII
10
DELISTED
Cardiovascular Systems, Inc.
CSII
$2.9M 2.95%
92,941
+46,300
+99% +$1.33M
2013 Q2
4 quarters
PKT
11
DELISTED
PROCERA NETWORKS INC NEW COM STK (DE)
PKT
$2.85M 2.9%
282,090
-1,600
-0.6% -$15.2K
2013 Q2
4 quarters
RTK
12
DELISTED
Rentech, Inc.
RTK
$2.63M 2.68%
101,598
+74,642
+277% +$1.66M
2013 Q2
4 quarters
SANW icon
13
DELISTED
S&W Seed Co
SANW
$2.52M 2.56%
20,413
+3,789
+23% +$502K
2013 Q2
4 quarters
UI icon
14
Ubiquiti
UI
$36.1B
$2.34M 2.39%
51,863
-11,500
-18% -$452K
2013 Q2
4 quarters
DRRX icon
15
DELISTED
DURECT Corp
DRRX
$2.31M 2.35%
+126,902
New +$1.78M
2014 Q2
0 quarters
CDZI icon
16
Cadiz
CDZI
$282M
$1.71M 1.74%
205,479
+152,720
+289% +$1.16M
2013 Q3
3 quarters
BKNG icon
17
Booking.com
BKNG
$119B
$1.68M 1.71%
+35,000
New +$1.68M
2014 Q2
0 quarters
AXGN icon
18
Axogen
AXGN
$2.08B
$1.53M 1.56%
550,607
– –
2013 Q3
3 quarters
CPRX icon
19
DELISTED
Catalyst Pharmaceutical
CPRX
$1.52M 1.55%
600,000
+317,500
+112% +$678K
2014 Q1
1 quarter
P icon
20
DELISTED
Pandora Media Inc
P
$1.47M 1.5%
49,900
-4,500
-8% -$117K
2013 Q2
4 quarters
SHOR
21
DELISTED
ShoreTel, Inc.
SHOR
$1.46M 1.48%
223,560
-20,268
-8% -$146K
2014 Q1
1 quarter
ARAY icon
22
Accuray
ARAY
$21.5M
$1.25M 1.27%
141,500
-116,800
-45% -$1.01M
2013 Q2
4 quarters
KFX
23
DELISTED
KOFAX LIMITED COM STK
KFX
$1.16M 1.18%
134,900
+81,300
+152% +$656K
2014 Q1
1 quarter
ENT
24
DELISTED
Global Eagle Entertainment Inc.
ENT
$1.14M 1.16%
3,672
– –
2013 Q3
3 quarters
SRL icon
25
Scully Royalty
SRL
$72.3M
$1.07M 1.09%
28,020
– –
2013 Q2
4 quarters
1
2 3 4

Similar funds

SFM
Socratic Fund Management Short Hills, New Jersey $12M AUM 39.3% 1-Year Est. Return
IACGFA
IDG-Accel China Growth Fund Associates Central, Hong Kong $13.2M AUM 31.6% 1-Year Est. Return
LS
Lupo Securities Chicago, Illinois $13.3M AUM 1.59% 1-Year Est. Return
NGPI
N.G. Partners II Palo Alto, California $9.65M AUM 70.44% 1-Year Est. Return
AP
AGTC Partners Cambridge, Massachusetts $13.6M AUM 15.62% 1-Year Est. Return
GRP
Geologic Resource Partners Boston, Massachusetts $9.22M AUM 48.14% 1-Year Est. Return
NVPV
Norwest Venture Partners VIII Palo Alto, California $9.22M AUM
AC
Amiya Capital London, United Kingdom $14.3M AUM 4.61% 1-Year Est. Return

Sophrosyne Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Sophrosyne Capital held 92 positions worth $98.2M, down 14% from $114M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sophrosyne Capital withdrew a net $12.8M in Q2 2014, closing 27 positions and reducing 24 holdings. Its most notable exit was Syngenta Ag, an estimated $6.05M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 47% a quarter earlier, followed by Technology and Financials.

Against the trend, Sophrosyne Capital opened a new position in DURECT Corp worth $2.31M.

  • Sophrosyne Capital's largest Q2 2014 buy was DURECT Corp: 126,902 shares worth $2.31M.
  • Sophrosyne Capital added most to Rentech, Inc. in Q2 2014, an estimated $1.66M increase.
  • Sophrosyne Capital's biggest Q2 2014 reduction was BioDelivery Sciences International, Inc., cutting an estimated $1.16M.
  • Sophrosyne Capital fully exited Syngenta Ag in Q2 2014, selling an estimated $6.05M.
  • Sophrosyne Capital's ten largest holdings make up 57% of its $98.2M portfolio in Q2 2014.
  • Sophrosyne Capital opened 14 new positions and closed 27 in Q2 2014.
  • Sophrosyne Capital's portfolio value fell 14% quarter-over-quarter to $98.2M.

Based on Sophrosyne Capital's 13F filing for Q2 2014, filed 14 Aug 2014.